SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is made as of July 24, 2018 by and between Nabriva Therapeutics US, Inc. (the “Company”), and Steven Gelone (the “Executive”) (together, the “Parties”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED & RESTATED THREE-WAY AGREEMENT By and Between LABORATORIOS ERN, S.A. and ERCROS, S.A. and ZAVANTE THERAPEUTICS,...Three-Way Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations
THIS AMENDED AND RESTATED THREE-WAY AGREEMENT (this “Agreement”) is made effective as of 28th July 2016 (the “Effective Date”), by and between Laboratorios ERN, S.A., a Spanish company with a principal place of business at 499 Pedro IV, 08020 Barcelona, Spain, represented by David Solanes López in his capacity as General Manager (“ERN”), Ercros, S.A., a Spanish company with a principal place of business at Paseo del Deleite s/n, 28300 Aranjuez, Spain, represented by Maria del Carmen Cruzado Rodríguez in her capacity as General Manager Pharmaceutical Division (“Ercros”), and Zavante Therapeutics, Inc., a Delaware corporation with a principal place of business at 11750 Sorrento Valley Road, Suite 250, San Diego, CA 92121, represented by Theodore R. Schroeder in his capacity as Chief Executive Officer (“Zavante”) (each individually a “Party” and collectively the “Parties”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omission. Manufacturing & Supply AgreementSupply Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • London
This Manufacturing and Supply Agreement (the “Agreement”) is made as of this 25 day of April, 2017 (the “Effective Date”), by and between Zavante Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, USA, with a place of business located at 11750 Sorrento Valley Road, Suite 250, San Diego California 92121, USA (“Zavante”) and Fisiopharma, S.r.l., a corporation organized under the laws of Italy, with a place of business located at Via Andrea Appiani, 22, 20121 Milano, Italy (“Fisiopharma”).
SORRENTO R&D OFFICE LEASEOffice Lease • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • California
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COMMERCIAL PACKAGING AGREEMENTCommercial Packaging Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
This Commercial Packaging Agreement (“Agreement”) is made as of this 26 day of December, 2017 (“Effective Date”), by and among Zavante Therapeutics, Inc., a Delaware corporation, with a place of business at 11750 Sorrento Valley Blvd., Suite 250, San Diego CA 92121 (“Zavante”), and AndersonBrecon Inc., an Illinois corporation, doing business as PCI of Illinois , with a place of business at 4545 Assembly Drive, Rockford, IL 61109 (together, “PCI”).
PACKAGING AND SUPPLY AGREEMENTPackaging and Supply Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations
This Packaging and Supply Agreement (the “Agreement”) effective as of 30 August 2018 (the “Effective Date”), is entered into by and between Sharp Corporation, a corporation organized and existing under the laws of Pennsylvania having its principal office at 7451 Keebler Way, Allentown, Pennsylvania 18106 (“Sharp”) and Nabriva Therapeutics US, Inc., a Delaware corporation, having its principal office at 1000 Continental Drive, Suite 600, King of Prussia, Pennsylvania 19406 (“Manufacturer”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Manufacturing & Supply AgreementSupply Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations
This Manufacturing and Supply Agreement (the “Agreement”) is made as of this 28 day of July, 2016 (the “Effective Date”) by and between Zavante Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, USA, with a place of business located at 11750 Sorrento Valley Road, Suite 250, San Diego, CA 92121, USA (“Zavante”), and Ercros, S.A., a Spanish company with a principal place of business at Paseo del Deleite s/n, 28300 Aranjuez, Spain (“Ercros”). Zavante and Ercros may each be referred to herein as a “Party” and, collectively, as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made by and between ICPD Holdings, LLC and Evelyn J. Ellis-Grosse (“Inventors”) and Zavante Therapeutics, Inc. (“Zavante”), a Delaware corporation having a place of business at 3605 Sandy Plains Road, Suite 240-218, Marietta, GA 30066.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED AND RESTATED PHARMACEUTICAL MANUFACTURING AND EXCLUSIVE SUPPLY AGREEMENT By and Between LABORATORIOS ERN, S.A....Manufacturing and Exclusive Supply Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations
THIS AMENDED AND RESTATED PHARMACEUTICAL MANUFACTURING AND EXCLUSIVE SUPPLY AGREEMENT (this “Agreement”) is made on the Effective Date by and between Laboratorios ERN, S.A., a Spanish Company with a principal place of business at 499 Pedro IV, 08020 Barcelona, Spain, represented by David Solanes López in his capacity as General Manager (“ERN”) and Zavante Therapeutics, Inc., a Delaware corporation with a principal place of business at 11750 Sorrento Valley Road, Suite 250, San Diego, CA 92121, represented by Theodore R. Schroeder in his capacity as Chief Executive Officer (“Zavante”) (each individually a “Party” and collectively the “Parties”).
STOCK PURCHASE AGREEMENT by and among SG PHARMACEUTICALS, INC., THE SELLERS NAMED ON ANNEX A AND JULIA FELICIANO AS SELLERS’ REPRESENTATIVE Dated as of May 5, 2015Stock Purchase Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • California
This STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 5, 2015, by and among SG Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), the persons listed as stockholders on Annex A hereto (collectively referred to herein as the “Sellers” and individually as a “Seller”), and Julia Feliciano, as Sellers’ Representative (as defined in Section 6.5(a)).
